Raju Mohan Acquires 238,248 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan bought 238,248 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average cost of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the acquisition, the chief executive officer now directly owns 1,913,276 shares in the company, valued at $3,501,295.08. The trade was a 14.22 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock. The shares were bought at an average cost of $2.01 per share, with a total value of $526,121.52.

Ventyx Biosciences Price Performance

NASDAQ:VTYX traded up $0.21 during trading hours on Monday, reaching $2.06. 2,159,733 shares of the company were exchanged, compared to its average volume of 2,033,156. The business has a 50 day moving average of $2.19 and a 200 day moving average of $2.64. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48. The company has a market capitalization of $145.66 million, a P/E ratio of -0.87 and a beta of 0.37.

Institutional Trading of Ventyx Biosciences

Several large investors have recently modified their holdings of VTYX. Palumbo Wealth Management LLC bought a new stake in Ventyx Biosciences during the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. raised its position in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Ventyx Biosciences during the 2nd quarter worth approximately $32,000. Intech Investment Management LLC acquired a new stake in shares of Ventyx Biosciences during the 3rd quarter worth approximately $42,000. Finally, The Manufacturers Life Insurance Company increased its stake in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on VTYX. Canaccord Genuity Group decreased their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Wells Fargo & Company lowered their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.